Compare PSTG & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSTG | PODD |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.4B | 22.1B |
| IPO Year | 2015 | 2007 |
| Metric | PSTG | PODD |
|---|---|---|
| Price | $70.60 | $304.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 19 |
| Target Price | $92.58 | ★ $359.00 |
| AVG Volume (30 Days) | ★ 5.2M | 765.6K |
| Earning Date | 12-02-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.15 | N/A |
| EPS | 0.38 | ★ 3.45 |
| Revenue | ★ $3,483,782,000.00 | $2,521,800,000.00 |
| Revenue This Year | $16.50 | $32.55 |
| Revenue Next Year | $15.25 | $20.39 |
| P/E Ratio | $185.45 | ★ $88.24 |
| Revenue Growth | 13.18 | ★ 27.11 |
| 52 Week Low | $34.51 | $230.05 |
| 52 Week High | $100.59 | $354.88 |
| Indicator | PSTG | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 36.04 | 40.94 |
| Support Level | $68.11 | $303.20 |
| Resistance Level | $96.50 | $317.34 |
| Average True Range (ATR) | 4.71 | 13.12 |
| MACD | -1.37 | -2.82 |
| Stochastic Oscillator | 7.33 | 3.14 |
Pure Storage Inc is a U.S.-based company that provides an enterprise data storage platform that transforms business through a dramatic increase in performance and reduction in complexity and costs. It generates revenue from two sources: product revenue, which includes the sale of integrated storage hardware and embedded operating system software; and subscription services revenue, which includes Evergreen Storage subscriptions, a unified subscription that includes Pure as-a-Service, Cloud Block Store, and Portworx. Subscription services revenue also includes professional services offerings such as installation and implementation consulting services.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.